Multaq (dronedarone tablets), an antiarrhythmic, has been made available by Sanofi-aventis for patients with atrial fibrillation (AF) or atrial flutter (AFL). Multaq is indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent AF or AFL, with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted.

Multaq is available in a 400mg dosage strength.

For more information call (800) 446-6267 or visit